Aortyx, a Barcelona-based MedTech scale-up, raises €13.8 million in a Series A funding round to bring their bioresorbable patch for treating aortic tears closer to market.
The funding round is led by Ship2B Ventures and Clave Capital, among others, with participation from various investors and angel investors.
The patch developed by Aortyx is a minimally invasive solution for aortic dissections, utilizing a steerable catheter to deploy a circular patch that plugs the tear in the aortic wall.
The team consists of four Co-founders, with expertise in various domains, and they have created a bioresorbable patch using an electrospinning technique inspired by spider silk.
Aortyx aims at reducing mortality and morbidity rates associated with aortic dissections, a condition affecting more than 50,000 Europeans annually, by providing a less invasive treatment option.
The technology has shown successful outcomes in animal and cadaver tests, with plans to begin first-in-human testing within two years, targeting vascular and cardiothoracic surgeons as key users.